INV-347 by Inversago Pharma for Obesity: Likelihood of Approval

INV-347 is under clinical development by Inversago Pharma and currently in Phase I for Obesity.

Feb 20, 2024 - 18:00

INV-347 is under clinical development by Inversago Pharma and currently in Phase I for Obesity.

Read the original article

Tags:

Previous Article

Opinion: STAT+: I’ve reported on the health of every president since Reagan. Her...

PF-07872412 by Pfizer for Streptococcal Pneumonia: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

CRISPR-based assay could revolutionise diagnosis of NTM infections

CRISPR-based assay could revolutionise diagnosis of NTM...

Mar 26, 2024

Ascidian launches first-ever clinical study of RNA exon editor for vision loss

Ascidian launches first-ever clinical study of RNA exon...

Jan 29, 2024

Laurus Labs and IIT Kanpur partner for new gene therapy products

Laurus Labs and IIT Kanpur partner for new gene therapy...

Jun 19, 2023